In vitro and in vivo interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib in non-Hodgkin lymphoma cells

Molecular Cancer Therapeutics (2014) - Comments
pubmed: 25239935 doi: 10.1158/1535-7163.mct-14-0220 issn: 1538-8514 issn: 1535-7163

Girija Dasmahapatra, Hiral Patel, Johnathan Friedberg, Steven N. Quayle, Simon S. Jones, Steven Grant